HCT116 | HT29 | SW620 | KM20L2 | |||||
---|---|---|---|---|---|---|---|---|
SF | p | SF | p | SF | p | SF | p | |
Monotherapy (relative to control) | ||||||||
IR | 0.029 (0.04) | <0.001 | 0.33 (0.02) | <0.001 | 0.079 (0.02) | <0.001 | 0.11 (0.002) | <0.001 |
HO | 0.97 (0.08) | 0.7 | 0.98 (0.03) | 0.6 | 0.62 (0.28) | 0.3 | 0.92 (0.01) | 0.01 |
VOR | 0.35 (0.04) | <0.001 | 0.78 (0.07) | 0.05 | 0.84 (0.04) | 0.07 | 0.66 (0.04) | 0.04 |
Combination therapy | ||||||||
IR-HO (relative to HO) | 0.13 (0.03) | <0.001 | 0.51 (0.05) | 0.002 | 0.36 (0.10) | 0.02 | 0.20 (0.02) | <0.001 |
VOR-HO (relative to HO) | 0.41 (0.05) | <0.001 | 0.88 (0.09) | 0.3 | 0.68 (0.14) | 0.1 | 0.68 (0.03) | 0.08 |
VOR-IR (relative to VOR) | 0.011 (0.004) | <0.001 | 0.18 (0.03) | <0.001 | 0.026 (0.02) | <0.001 | 0.066 (0.02) | <0.001 |
VOR-IR-HO (relative to VOR-HO) | 0.020 (0.005) | <0.001 | 0.24 (0.02) | <0.001 | 0.052 (0.03) | <0.001 | 0.040 (0.006) | <0.001 |